EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Model‐based analysis of therapeutic efficacy of blonanserin and risperidone in schizophrenia patients and effects on prolactin: A randomized double‐blind study

Wenjuan Yu iD, Lei Lei, Yimin Yu, Yan Li, Yifeng Shen, Huafang Li

Human Psychopharmacology: Clinical and Experimental · 2020-01 · 35 (1)

DOI: 10.1002/hup.2717 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Human Psychopharmacology: Clinical and Experimental, online erschienen am 14.12.2019. Verfasst von Wenjuan Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Models, Statistical. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study examined randomized controlled trial data for blonanserin and risperidone in Chinese schizophrenia patients ( N = 264). Data related to historical changes in the Positive and Negative Syndrome Scale (PANSS) were used to successfully construct a longitudinal E max model. Results: (a) The efficacy of the two drugs was similar after week 8, showing a small difference in PANSS reduction. (b) Using the model, we predicted that each 5‐point increase in the baseline FPOS (positive score in PANSS five‐factor subscales) leads to a decrease in the PANSS total scores at week 8 for 2 points in patients administered blonanserin. (c) The effect of blonanserin on prolactin (PRL) elevation was less. The model was used to predict that prolactin elevations in patients administered risperidone were 2.41‐fold of those in patients administered blonanserin. (d) Model quantitation showed that gender is a risk factor for prolactin elevation. Prolactin elevations in female patients were 2.95‐fold of the value in male patients administered the same drug. The model demonstrated Blonanserin has similar antischizophrenic efficacy and less serum prolactin rising compared to risperidone in Chinese patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Models, StatisticalAdolescentAdultAntipsychotic AgentsDouble-Blind MethodFemaleHumansMaleMiddle AgedPiperazinesPiperidinesProlactinRisperidoneSchizophreniaSex FactorsYoung Adult

Stichwörter der Autor:innen

blonanserinmodel-based analysispharmacodynamicsrisperidoneschizophrenia

Substanzen

Antipsychotic AgentsPiperazinesPiperidinesProlactinblonanserinRisperidone

Autor:innen und Institutionen

  • Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Sumitomo Pharmaceuticals(Suzhou) Co., Ltd., Shanghai, China.
  • Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.
  • Clinical Research Center, Shanghai Jiao Tong university School of Medicine, Shanghai, China.

ORCID-Profile: Wenjuan Yu

Zitieren

APA

Yu, W., Lei, L., Yu, Y., Li, Y., Shen, Y., & Li, H. (2020). Model‐based analysis of therapeutic efficacy of blonanserin and risperidone in schizophrenia patients and effects on prolactin: A randomized double‐blind study. Human Psychopharmacology: Clinical and Experimental, 35(1). https://doi.org/10.1002/hup.2717

Vancouver

Yu W, Lei L, Yu Y, Li Y, Shen Y, Li H. Model‐based analysis of therapeutic efficacy of blonanserin and risperidone in schizophrenia patients and effects on prolactin: A randomized double‐blind study. Human Psychopharmacology: Clinical and Experimental. 2020;35(1). doi:10.1002/hup.2717

BibTeX
@article{Yu2020,
  author = {Yu, Wenjuan and Lei, Lei and Yu, Yimin and Li, Yan and Shen, Yifeng and Li, Huafang},
  title = {Model‐based analysis of therapeutic efficacy of blonanserin and risperidone in schizophrenia patients and effects on prolactin: A randomized double‐blind study},
  journal = {Human Psychopharmacology: Clinical and Experimental},
  year = {2020},
  volume = {35},
  number = {1},
  doi = {10.1002/hup.2717}
}
Kostenlos starten →